Non-O blood groups as independent predictors of chronic subdural hematoma recurrence in antithrombotic-naive patients: risk mitigation by prior aspirin use and new perspectives for stratification.
Non-O blood groups independently predict recurrence after chronic subdural hematoma surgery.
Non-O blood groups as independent predictors of chronic subdural hematoma recurrence in antithrombotic-naive patients: risk mitigation by prior aspirin use and new perspectives for stratification.
Recurrence after surgical treatment of chronic subdural hematoma (chronic subdural hematoma) remains insufficiently understood.
Given the known differences in clotting propensity among ABO blood groups and the frequent use of antiplatelet and/or anticoagulant therapy (anticoagulant therapy) in the chronic subdural hematoma population, this study aimed to investigate the impact of ABO blood groups on postoperative recurrence risk.
The authors conducted a retrospective analysis of patients with symptomatic chronic subdural hematoma who underwent surgery at their institution between June 2012 and December 2023.
non-O blood types raise reoperation odds more than threefold
In patients without prior anticoagulant therapy use (n = 360), univariate analysis showed that non-O blood groups had significantly higher recurrence rates than blood group O (19.4% vs 8.7%, p = 0.006).
Comparing patients with prior acetylsalicylic acid (aspirin) use (n = 190) with those without prior anticoagulant therapy use, univariate analysis revealed that prior aspirin therapy was associated with a significantly lower recurrence rate among non-O (6.9% vs 19.4%, p = 0.002), and particularly A (8% vs 21%, p = 0.011), blood groups.
This large-scale study demonstrated that non-O blood groups, and particularly A blood groups, are independent predictors of increased chronic subdural hematoma recurrence in patients without prior anticoagulant therapy use.
These findings support the development of a scoring system based on blood groups, particularly for patients with groups A and O, to improve recurrence risk stratification and to tailor treatment plans.
In contrast, prior aspirin use in these groups was an independent predictor of markedly reduced recurrence rates, comparable to those of blood group O.